Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma
NCT00692770Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2008
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Recurrence Free Survival at 4 years. Started Aug 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00692770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00692770.